Skip to main content

Table 2 Anticancer effects of samples against A-375 and MDA-MB-468

From: Chitosan nanoparticles containing limonene and limonene-rich essential oils: potential phytotherapy agents for the treatment of melanoma and breast cancers

Samples

A-375

MDA-MB-468

LCL*

IC50*

UCL*

LCL

IC50

UCL

limonene

176.18

246.05

343.62

1636.44

2118.94

2743.71

LimChiNPsa

13.53

30.24

67.58

498.29

650.70

849.72

CAEOb

4832.01

10,564.00

23,095.00

781.41

2037.53

5312.86

CAChiNPsc

15.66

55.00

193.16

144.20

240.44

400.92

CLEOd

0.49

10.54

228.46

57.41

137.03

327.06

CLChiNPse

3.270

0.124

0.05

10.41

40.32

156.14

CSEOf

0.01

0.02

0.03

139.97

168.00

201.65

CSChiNPsg

0.02

0.03

0.05

2.74

23.65

204.43

  1. a chitosan nanoparticles containing limonene, b C. aurantium EO, c chitosan nanoparticles containing C. aurantium EO, d C. limon EO, e chitosan nanoparticles containing C. limon EO, f C. sinensis EO, chitosan nanoparticles C. sinensis EO
  2. * The half-maximal inhibitory concentration or IC50 (μg/mL) with lower and upper confidence limits; LCL and UCL
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us